Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Interferes with bacterial protein synthesis by binding to the 50S ribosomal subunit and inhibiting peptide-chain formation. Clinical antibacterial activity and spectrum depend on the product and local susceptibility.
Indications / reported uses
Historically used in selected respiratory tract infections caused by susceptible Gram-positive bacteria in countries where clofoctol was authorised; current marketed status and role are limited
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Clofoctol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Clofoctol Permitted Daily Exposure (PDE) report (the Clofoctol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Clofoctol Occupational Exposure Limit (OEL) report (the Clofoctol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.